Posted by Michael Wonder on 28 Mar 2020
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
28 March 2020 - EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data.
Novartis, a leader in rheumatology and immuno-dermatology, today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Cosentyx (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
